DENTSPLY SIRONA (XRAY) Cuts 2026 Guidance, Is The 24% Undervalued View Still Credible?

DENTSPLY SIRONA (XRAY) reduced its 2026 guidance. Analysts previously viewed the stock as 24% undervalued, but this adjustment may impact that assessment. The change in outlook could influence investor decisions.

Original reporting
Published Nov 8, 2026, 5:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 8, 2026, 5:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DENTSPLY SIRONA (XRAY) Cuts 2026 Guidance, Is The 24% Undervalued View Still Credible? — source image
Decision brief

The 30-second read

$XRAYBearishHigh
01

Why it matters

The guidance cut is the primary new fact, likely driving immediate price action.

02

Market read

Guidance cuts are material for traders; XRAY is the sole subject.

03

What to watch

Potential cost‑saving initiatives or upcoming product launches not reflected in the guidance.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

The article is an AI‑generated summary of Dentsply Sirona's guidance revision, with no additional commentary.

Company-level read

Ticker impact

$XRAYBearishHigh confidence
Context

Dentsply Sirona cut its 2026 guidance, indicating lower future earnings expectations.

Expected impact

likely downward pressure as investors price in lower guidance

Evidence & confidence

Guidance cuts historically lead to immediate price declines, especially for a high‑valuation stock.

Market effects

May weigh on dental equipment and broader medical device sector.

U.S. market likely sees modest pullback in health‑care stocks.

Limited to investors tracking Dentsply Sirona and related peers.

Counterpoint

If the cut reflects temporary market noise, the stock could rebound on long‑term fundamentals.

Key entities

  • Dentsply Sirona

    Dental equipment manufacturer (ticker XRAY).

Related articles

$XRAYHighAI 8/10

XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds

XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.

MedAI 8/10

Dentsply Sirona Lowers 2026 EPS Outlook After Third-Quarter Sales Slide

Dentsply Sirona (XRAY) lowered its 2026 adjusted EPS outlook to $1.20-$1.30 after Q3 sales fell 7.6% to $836M and adjusted EPS dropped 29.4% to $0.29. The company expects $3.5B in 2026 sales, down from its prior $3.5B-$3.6B forecast. Q3 net loss was $2M, improved from a $427M loss in Q3 2025. Sales varied across business segments, with Wellspect Healthcare up 10.1%.

$XRAYMedAI 8/10

DENTSPLY SIRONA Q3 Earnings Call Highlights

DENTSPLY SIRONA reported Q3 earnings with a $39M pretax accounting benefit, not expected to recur. Operating cash flow declined to $32M. Wellspect Healthcare revenue rose 10%, while dental segments saw declines. The company repurchased 1.2M shares and plans $120M in savings for 2026. Management expects continued investment in growth areas.

HighAI 8/10

DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript

DENTSPLY SIRONA (XRAY) reported Q3 2026 revenue of $836M, down 7.6%, and adjusted EPS of $0.29. The company lowered its full-year guidance to $3.5B in sales and $1.20-$1.30 in adjusted EPS, citing business pressures and investment in growth initiatives. Wellspect Healthcare saw record sales growth, while other segments faced challenges.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) stock trades down, here is why

Dentsply Sirona (XRAY) shares fell 7% after reporting a Q3 2026 GAAP loss of $0.01 per share and lowering its full-year outlook. Net sales were $836M, missing estimates. The company now expects 2026 net sales of $3.5B and adjusted EPS of $1.20-$1.30. Shares are down 17.4% YTD and 36.6% below their 52-week high.

$XRAYMed

BofA cuts Dentsply Sirona stock price target on guidance reset

BofA Securities reduced its price target for Dentsply Sirona (XRAY) to $14 from $17, citing disappointing Q3 results and a revised 2026 EPS guidance of $1.10. The stock trades near its 52-week low at $8.14. BofA noted positive developments in some segments but expects growth stabilization over time. XRAY's Q3 earnings and revenue missed estimates, leading to a stock price drop.